Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

Ainsworth, Stuart ORCID: https://orcid.org/0000-0002-0199-6482, Menzies, Stefanie ORCID: https://orcid.org/0000-0002-9273-9296 and Pleass, Richard ORCID: https://orcid.org/0000-0001-7438-8296 (2020) 'Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19'. Wellcome Open Research, Vol 5, Issue 115.

Preview

Text Ainsworth et al 2020_Animal derived antibodies_Wellcome Open Res-June-20.pdf - Published Version Available under License Creative Commons Attribution. Download (609kB) | Preview

Abstract

Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may

Item Type:	Article
Subjects:	QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies WA Public Health > WA 105 Epidemiology WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections WH Hemic and Lymphatic Systems > Hematologic Diseases. Immunologic Factors. Blood Banks > WH 400 Fluid elements. Plasma. Serum. Blood proteins. Blood protein disorders
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI):	https://doi.org/10.12688/wellcomeopenres.15990.1
Depositing User:	Mary Creegan
Date Deposited:	22 Jun 2020 12:21
Last Modified:	22 Jun 2020 12:21
URI:	https://archive.lstmed.ac.uk/id/eprint/14769

Statistics

View details

Actions (login required)

Edit Item